Objective The recognition of clinical symptoms is critical to developing an effective therapeutic strategy for aortic valve stenosis (AS). Although AS is common, little is known about the factors influencing the natural history of AS patients who are 80 years of age older in advanced aging societies. We investigated the natural history and indications for valve procedures in AS patients of 80 years of age or older. Methods The medical records of 108 consecutive AS patients (moderate grade or higher) who are 80 years of age or older (mean age, 84.2±3.9 years; female, 65 patients) were reviewed to investigate their symptoms, the development of congestive heart failure, the incidence of referral for aortic valve replacement and death. The median duration of follow-up was 9 months (interquartile range, 2 to 25 months). Results The probability of remaining free of events (valve replacement and death) was 29±13% in all patients. There was no significant difference in the aortic valve area of the symptomatic and asymptomatic patients (0.85±0.28 cm 2 vs. 0.88±0.25 cm 2 , p=0.59). The aortic valve (AV) velocity and AV area index were predictors of subsequent cardiac events (p<0.05). Conclusion The severity of AS was the only factor to affect the prognosis of AS patients who were 80 years old of age or older. It is necessary to frequently monitor the subjective symptoms of such patients and to objectively measure the AV area.
Introduction
Aortic valve stenosis (AS) is now the most common form of native heart disease. The growth rate of the elderly population has continued to increase and the prevalence of AS sharply increases with age (1) . Thus, as life expectancy grows longer, valvular heart disease in the elderly is becoming an increasingly important health issue (2) , and the population of elderly AS patients is expected to grow in the future (3) . With the growing number of elderly AS patients, the use of echocardiography and the acceptance of surgical procedures are increasing in this population. The therapeutic management of AS patients depends on the hemodynamic severity of the stenosis and the presence of symptoms (angina, syncope, dyspnea), as the onset of symptoms and left ventricular (LV) systolic dysfunction are associated with a poor prognosis (4) . However, it is difficult to use these variables to assess the risks of AS patients who are 80 years of age or older. The decision to operate raises specific problems in the elderly, because of higher incidence of operative mortality and morbidity, particularly in those who are deemed to be at high surgical risk (5) .
Although AS is common, little data is available regarding the factors that influence the natural history of AS patients of 80 years of age or older in advanced aging societies. The onset of symptoms is the main factor in considering surgery and symptomatic patients had a higher incidence of events related to progressive AS (6) . Over the last decade, the early outcomes after heart valve surgery have improved, both in terms of operative mortality and quality of life, but age influences the decision to perform aortic valve replacement (AVR) (7). To address this issue, this study investigated the natural history and the indications for valve procedures in AS patients who were 80 years of age or older.
Materials and Methods

Patient population
All of the patients who were 80 years of age or older, who were examined at our outpatient clinic for valvular heart disease between 2006 and 2012 and who were found to have a stenotic native aortic valve (AV) area of ! 1.5 cm 2 were included in the present study. This study protocol was approved by the ethical committee of Shimane University Faculty of Medicine. Patients with significant associated valve disease (aortic or mitral regurgitation of a grade higher 2/4 or mitral stenosis with a valve area of ! 1.5 cm 2 and prior valve replacement surgery) were excluded from the study. According to these criteria, 108 patients (mean age, 84.2±3.9 years; female, 65 patients; average AV area, 0.85± 0.27 cm 2 ; average AV peak velocity, 4.1±0.9 m/s) were identified (Table 1 , 2).
The clinical data included age, gender, body surface area, body mass index, smoking history, documented diagnosis of atrial fibrillation, diabetes mellitus, hypertension, dyslipidemia, hemodialysis, coronary artery disease (history of myocardial infarction, coronary artery stenosis on coronary angiography), and pertinent current and past medical and surgi-cal history. Special attentions was paid to the documented symptoms that were potentially associated with AS, including angina, chest pain, syncope and dyspnea or other evidence of heart failure.
Echocardiographic data
Our echocardiographic database was searched for patients with moderate and severe AS (defined as a valve area ! 1.5 cm 2 ). All of the patients underwent standard echocardiographic examinations which that included comprehensive 2-dimensional and Doppler echocardiography. The maximal AV velocity was recorded at the apical, right parasternal, or suprasternal multiple transducer positions, and the AV area was calculated with the continuity equation using the LV outflow tract diameter and flow velocity. The peak and mean aortic pressure gradient (PG) were calculated using the Bernoulli equation. In each patient, the internal dimensions of the LV at both the end-diastole (LVDD) and end-systole (LVSD) were measured using 2D images from the parasternal long-axis acoustic window. The LV mass was calculated using the linear method (8) . The LV end-diastolic volume (EDV) and the end-systolic volume (ESV) were measured using the biplane disk method. The LVEF was calculated using the following equation: 100×(EDV-ESV)/EDV. The left atrial (LA) volume was also measured using the biplane disk method. The transmitral flow velocity was recorded from the apical 4-chamber window by placing the sample volume at the level of the mitral valve leaflet chips. The peak early mitral inflow velocity (E), peak late mitral inflow velocity (A), E/A ratio, and deceleration time (DT) of the E wave were obtained. The tissue Doppler images of the septal and lateral annulus motion of the LV were viewed to measure the early diastolic velocity (E'). The ratio between peak E and E' was calculated (E/E'). Diastolic dysfunction was graded according to the guidelines of the American Society of Echocardiography (9) . The transtricuspid pressure gradient (TRPG) was measured using the tricuspid regurgitation velocity.
Follow-up
All study patients were followed up after their initial examination for moderate and severe AS. The follow-up information was obtained by a detailed review of all medical records. Information about the development of cardiac symptoms, AVR, and death was obtained from their physicians. The classical symptoms of AS are angina, syncope, heart failure and a New York Heart Association or Canadian Cardiovascular Society class of II or more. For the assessment of the outcome, the end points were death (all cause death) or AVR during the follow-up period.
Statistical analysis
The quantitative variables are shown as the mean±SD. Normally distributed groups of quantitative variables were compared using the t-test of two independent-samples. Groups with abnormally distributed continuous variables were compared using the Wilcoxon test. The chi-squared test was used to compare the samples of qualitative variables. The effect of potential prognostic factors (age, sex, body mass index, smoking, atrial fibrillation, diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, LVEF, LVDD, LVEDV, AV area, AV area index, AV peak velocity, PG) on the likelihood of event-free survival was assessed using simple and multiple Cox regression models. The strength of effects was quantified using unadjusted and adjusted hazard ratio estimates. The overall event-free survival was described using the Kaplan-Meier method and compared using the log rank test; the SE was also shown for the estimated event-free survival population. The assumption of proportional hazards was assessed by adding the interactions of all of the prognostic factors to the log of time. The predictors of survival were analyzed by the weighted Cox regression method to estimate the hazard ratios. A univariable analysis of the predictive factors of the outcome was performed using a Cox model. Variables with p values of <0.2 were entered into a multivariate Cox model and selected by a backward procedure with a threshold of p=0.05. Supplemental multivariate analyses were conducted with the forced inclusion of age, symptomatic status and one of echo variables (AV area index). In all of the statisticalanalyses, p values of <0.05 were considered to indicate statistical significance. All statistical analyses were performed using SPSS Statistics for Macintosh, version 18.0 (SPSS, Inc., Chicago, USA).
Results
We identified 108 patients for whom data collection and the follow-up information were 100% complete. Atrial fibrillation occurred in 30 patients (28%), while seven patients required hemodialysis therapy. The median duration of follow-up was 9 months (interquartile range, 2 to 25 months).
Baseline characteristics
The baseline characteristics of the patients are shown in Table 1 . The cohort included 43 men (40%) and 65 women (60%). The mean peak velocity was 4.1±0.9 m/s, the mean pressure gradient was 42.2±19.4 mmHg, and the mean AV area was 0.85±0.27 cm 2 . Eighty patients were symptomatic at the time of their enrollment: chest pain (n=26), dyspnea (n=47), and syncope (n=7). The asymptomatic and symptomatic groups were defined according to baseline clinical characteristics (Table 1 , 2). There were no significant differences in the sex, body surface area, body mass index, atrial fibrillation, coronary artery disease, diabetes mellitus, hypertension, dyslipidemia, hemodialysis, drug therapy, E/A, E', E/E', AV area, AV area index, AV velocity, TRPG, LV mass index, peak AV pressure gradient, mean AV pressure gradient, LV volumes, LA volume index or diastolic dysfunction grade (Table 1 , 2). However, there was a significant difference in the age and smoking status of the asymptomatic and symptomatic groups (both p<0.05; Table 1 ). An analysis of the echocardiographic data indicated significant differences in the EF and LVDD values (both p<0.05) of the asymptomatic and symptomatic groups ( Table 2 ). There were no significant differences in the age, sex, body surface area, smoking, atrial fibrillation, coronary artery disease, diabetes mellitus, hypertension, dyslipidemia, hemodialysis, drug therapy, E/A, E', E/E', EF, LVDD, TRPG, LV mass index, LV volumes, LA volume index, or diastolic dysfunction grades of the event and no-event groups (Table 3, 4) . There was a significant difference in the body mass index of the patients in the event and no-event groups (p<0.05; Table 3 ). An analysis of the echocardiographic data showed that there were significant differences in the AV area, AV area index, AV velocity, peak AV pressure gradient of the event and no-event groups (all p< 0.05; Table 4 ).
The univariate and multivariate models for predicting the outcomes are shown in Table 5 . The AV area index and AV velocity were found to be the most powerful predictors of outcome (p<0.05) ( Table 5 ). In this study, neither a symptomatic nor asymptomatic status was found to be a significant independent predictor of mortality.
Event-free survival
Thirty-eight events were observed, including AVR in 26 patients and death in 16 patients (including 4 patients who died after AVR). The dominant reason for a symptomatic patient not undergoing AVR was patient or family refusal. The rates of event free survival were 70±5% at 1 year, 62±6 % at 2 years, 47±8% at 3 years, 43±8% at 4 years, 43±8 % at 5 years, and 29±13% at 6 years. Sixteen patients died during the follow-up period; 14 of the 16 patients who died were symptomatic. Twenty-six patients underwent AVR. Surgery was indicated due to the presence of symptoms. Three asymptomatic patients underwent elective surgery due to the development of symptoms. The risk of event-free survival was lower in the symptomatic group than in the asymptomatic group. However, the presence of symptoms did not affect event-free survival rate among patients with moderate and severe AS. The event-free survival rates in asymptomatic patients (n=28) were 76±10% at 1 year, 65± 14% at 2 years, 65±14% at 3 years, 65±14% at 4 years, 65± 14% at 5 years, and 65±4% at 6 years. The event-free survival rates in symptomatic patients (n=80) were 68±6% at 1 year, 61±6% at 2 years, 42±8% at 3 years, 38±9% at 4 years, 38±9% at 5 years, and 19±14% at 6 years ( Fig. 1) . The presence of symptoms did not affect the event-free survival rate (p=0.085, χ 2 =2.72, Fig. 1 ). The AV area and peak AV velocity affected the event-free survival rate among the octogenarian patients of our study. The outcome of patients with an AV area of <1.0 cm 2 was significantly different from that of patients with an AV area of between 1.0 and 1.5 cm 2 (p<0.001; χ 2 =14.19; Fig. 2 ). The event-free survival rates of patients with an AV area of between 1.0 and 1.5 cm 2 (n=37) were 90±6% at 1 year, 85± 7% at 2 years, 69±12% at 3 years, and 69±12% at 4 years. The event-free survival rates were worse in patients with AV area of ! 1.0 cm 2 (n=71): 60±7% at 1 year, 50±8% at 2 years, 32±10% at 3 years, and 24±10% at 4 years (p<0.001; Fig. 2) .
The event-free survival rates of patients with a peak aortic jet velocity of ! 4.0 m/s (n=58) were 88±5% at 1 year, 78± 7% at 2 years, 62±10% at 3 years, and 62±10% at 4 years. The event-free survival rates were significantly worse for patients with a peak aortic jet velocity of between 4.0 and 5.0 m/s (n=29): 55±11% at 1 year, 55±11% at 2 years, 37±17% at 3 years, and 37±17% at 4 years. The event-free survival rates further decreased for patients with a peak aortic jet velocity of >5 m/s (n=21): 37±13% at 1 year, 28±12% at 2 years, 18±11% at 3 years, and 9±9% at 4 years (p<0.001; χ 2 =21.48; Fig. 3 ). The event-free survival rates were significantly worse for patients with very severe AS, as defined by a peak AV velocity of >5 m/s. There were 22 patients with an AV area of ! 1.0 cm 2 and a peak aortic jet velocity of < 4.0 m/s (low-flow low-gradient). The event rates did not differ to a statistically significant extent between the low-flow low-gradient group (6 events, 27.3%) and the high gradient group (32 events, 37.2%).
The presence of coronary artery disease was not of additional prognostic importance in this patient group. Furthermore, treatment with ACEI or ARBs (n=59), diuretic drugs (n=57), calcium antagonists (n=59), statins (n=33), or β-blockers (n=26) did not affect the event-free survival rate.
Discussion
The present study was performed to assess the outcomes of a subset of patients with moderate and severe AS who were 80 years old or older. We found that the risk levels of the patients could be stratified according to the aortic jet velocities and the AV area.
In many patients, the development of symptoms is clear, but some asymptomatic patients are difficult to assess due to inactivity or under-reporting (10) . Some patients with moderate AS may develop severe AS during the follow-up period, because they, or their physicians, are less aware of the potential hazards before diagnosis (11) . Although a watchful waiting approach is generally justified in asymptomatic patients with severe AS, due to the high event rate and the possibility of rapid deterioration in patients who are 80 years of age or older, the consideration of early elective surgery might be worthwhile, even when patients are still asymptomatic (12) .
Recently, there has been a clear decrease in operative risk, the operative mortality of isolated AVR in older adults is 5-15%, including selected octogenarians and even nonagenarians (13) . Among symptomatic patients who did not undergo surgery, most decided against surgery because the presence of comorbidities resulted in an acceptable degree of operative risk, the patient's decision was the second most common reason for the refusal of surgery (14) . Symptomatic patients with hemodynamically significant AS should be considered for AVR irrespective of age, and valve replacement may be feasible and the degree of risk might be considered acceptable due to the marked improvement in the quality of life that can be expected (4) .
The present study shows that peak aortic jet velocity is an important predictor of the outcome in patients with a broad range of disease severity, and that a peak aortic jet velocity of " 4.5 m/s was associated with a significantly worse out- come, with an increased risk of AVR or death (15) . The maximum aortic velocity, mean transvalvular gradient, and AV area measurement have been well validated as predictors of clinical outcome (16) . The subgroup of patients with a peak aortic jet velocity of >5 m/s had a poorer event-free survival rate and presented with more severe symptoms than the patients with a peak aortic jet velocity of 4.0 to 5.0 m/s or a peak aortic jet velocity of ! 4.0 m/s. The peak aortic jet velocity thus yielded important prognostic information in this group of AS patients who were 80 years of age or older. Advanced age is often used to justify a decision to not perform surgery but suitably selected patients may derive considerable improvement in their burden of symptoms and overall quality of life after successful intervention (17) . The present study is associated with several limitations. It was a single-center retrospective study and may not reflect experiences at other sites. The follow-up mortality data was collected, but the quality of life was not assessed. Furthermore, the possibility of a selection bias cannot be excluded in the group that proceeded to surgery. The study was not designed to assess or compare the mortality rate between the surgical and medical groups. Because transcatheter aortic valve replacement (TAVR) has been approved for clinical use, as the experience with TAVR increases, it will be offered to more patients as an alternative to AVR (18, 19) . Future studies with a large number of cases are warranted.
Conclusion
The severity of AS affected the prognosis of even asymptomatic patients who were 80 years of age or older. Thus the frequent monitoring of their subjective symptoms combined with the objective measurement of AV area is necessary.
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